Immunovant annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
2026
Immunovant Debt-to-Assets Ratio Growth & History (IMVT)
Immunovant's debt-to-assets ratio was 0.00 for fiscal 2026.
View full Immunovant company overviewImmunovant annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | 0.00 | −0.00 | −40.41% |
| 2025 | 2025-03-31 | 0.00 | −0.00 | −39.04% |
| 2024 | 2024-03-31 | 0.00 | −0.00 | −93.11% |
| 2023 | 2023-03-31 | 0.00 | −0.00 | −34.44% |
| 2022 | 2022-03-31 | 0.00 | −0.00 | −44.65% |
| 2021 | 2021-03-31 | 0.01 | 0.01 | — |
| 2020 | 2020-03-31 | 0.00 | — | — |
Immunovant quarterly debt-to-assets ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q4.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | 0.00 | −0.00 | −40.41% |
| Q4 2025 | 2025-03-31 | 0.00 | −0.00 | −39.04% |
| Q3 2025 | 2024-12-31 | 0.00 | −0.00 | −87.30% |
| Q2 2025 | 2024-09-30 | 0.00 | −0.00 | −95.66% |
| Q1 2025 | 2024-06-30 | 0.00 | −0.00 | −95.53% |
| Q4 2024 | 2024-03-31 | 0.00 | −0.00 | −93.11% |
| Q3 2024 | 2023-12-31 | 0.00 | −0.00 | −87.01% |
| Q2 2024 | 2023-09-30 | 0.00 | −0.00 | −49.97% |
| Q1 2024 | 2023-06-30 | 0.00 | −0.00 | −42.41% |
| Q4 2023 | 2023-03-31 | 0.00 | −0.00 | −34.44% |
| Q3 2023 | 2022-12-31 | 0.00 | 0.00 | +66.72% |
| Q2 2023 | 2022-09-30 | 0.00 | 0.00 | +120.08% |
| Q1 2023 | 2022-06-30 | 0.00 | −0.00 | −42.33% |
| Q4 2022 | 2022-03-31 | 0.00 | −0.00 | −44.65% |
| Q3 2022 | 2021-12-31 | 0.00 | −0.01 | −75.40% |
| Q2 2022 | 2021-09-30 | 0.00 | −0.01 | −77.08% |
| Q1 2022 | 2021-06-30 | 0.01 | −0.01 | −45.55% |
| Q4 2021 | 2021-03-31 | 0.01 | 0.01 | — |
| Q3 2021 | 2020-12-31 | 0.01 | — | — |
| Q2 2021 | 2020-09-30 | 0.01 | — | — |
| Q1 2021 | 2020-06-30 | 0.01 | — | — |
| Q4 2020 | 2020-03-31 | 0.00 | — | — |
Immunovant debt-to-assets ratio trends
Over the last five fiscal years, Immunovant's debt-to-assets ratio decreased from 0.01 to 0.00, a change of −0.01. The latest reported quarter, Q4 2026, shows 0.00.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant source filings ↗